

Fall 11-2-2015

# Considerations for an incubation chamber for continuous viral inactivation

Raquel Orozco

*Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA, raquel.orozco@boehringer-ingelheim.com*

Nancy Guillen

*Cell Culture, Boehringer Ingelheim Fremont Inc. CA USA*

Loleta Chung

*Clinical Supply, Boehringer Ingelheim Fremont Inc. CA USA*

Scott Godfrey

*Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA*

Jon Coffman

*Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA*

Follow this and additional works at: [http://dc.engconfintl.org/biomanufact\\_ii](http://dc.engconfintl.org/biomanufact_ii)



Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

## Recommended Citation

Raquel Orozco, Nancy Guillen, Loleta Chung, Scott Godfrey, and Jon Coffman, "Considerations for an incubation chamber for continuous viral inactivation" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). [http://dc.engconfintl.org/biomanufact\\_ii/66](http://dc.engconfintl.org/biomanufact_ii/66)

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).

## CONSIDERATIONS FOR AN INCUBATION CHAMBER FOR CONTINUOUS VIRAL INACTIVATION

Raquel Orozco, Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA  
raquel.orozco@boehringer-ingelheim.com

Nancy Guillen, Cell Culture, Boehringer Ingelheim Fremont Inc. CA USA  
Loleta Chung, Clinical Supply, Boehringer Ingelheim Fremont Inc. CA USA  
Scott Godfrey, Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA  
Jon Coffman, Bioprocess Engineering, Boehringer Ingelheim Fremont Inc. CA USA

Key words: viral inactivation, continuous bioprocessing

Continuous bioprocessing offers numerous benefits that have been highlighted recently in the literature. While substantial research efforts have allowed for relevant developments in continuous cell culture processes, downstream challenges, such as continuous viral inactivation, have not been addressed. The purpose of this work is to design a chamber that incubates a continuous product stream for a desired incubation time, typically for 1 hour. Since plug-flow cannot be achieved at typical incubation times and flow rates, one of the biggest challenges is to address dispersion of the product stream. Since several logs of viral clearance should be achieved during a virus removal step, the restriction is that only 1-10ppm of the original product should exit the chamber before the specified time. In this work, an initial design is chosen such that the incubation chamber is easy to handle, has a small footprint, and there are no pressure concerns at the desired flow rates. Pulse response experiments have been performed to generate cumulative residence time distribution functions. The average residence time distribution function was used to find the time at which 1 ppm of the original tracer concentration passes through the chamber. An orthogonal method should be used to verify that the diluted tracer concentration falls under the predicted value at the desired time. Thus, the starting tracer solution must be concentrated enough such that a concentration of 1 ppm can be measured by a highly sensitive technique. In this work, a tracer solution and a method of detection were selected. Preliminary results of chamber design will be shown and current challenges will be shared.